STOCK TITAN

IONS insider sale notice: 6,849 shares to be sold on Nasdaq

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ionis Pharmaceuticals, Inc. filed a Form 144 notice reporting a proposed sale of 6,849 shares of common stock, with an aggregate market value of $472,718, to be executed approximately on 10/06/2025 through Stifel Nicolaus & Company on Nasdaq. The shares were acquired as Restricted Stock Units from the issuer on 01/15/2025 and paid for in cash on the same date. The filer reports total shares outstanding of 159,391,229. The notice also lists three prior sales by the same person, Eric Swayze, totaling 38,244 shares sold on 09/02/2025, 10/01/2025, and 10/02/2025, generating combined gross proceeds of $2,346,609. The signer affirms no undisclosed material adverse information and references Rule 10b5-1 conditions.

Positive

  • Planned sale is modest: only 6,849 shares versus 159,391,229 outstanding
  • Securities were acquired as RSUs on 01/15/2025, indicating compensation-related origin
  • Recent prior sales disclosed 38,244 shares), showing transparency in insider transactions

Negative

  • Concentrated recent selling: 38,244 shares sold in three transactions generating $2,346,609, which may be viewed as insider liquidity
  • No Rule 10b5-1 plan date provided in the notice, leaving uncertainty about pre-planned sale protection

Insights

TL;DR: Reported sales are routine insider liquidity from RSUs and consistent with Rule 144 disclosures.

The filing shows a planned sale of 6,849 shares RSUs on 01/15/2025) with an aggregate market value of $472,718, through Stifel on 10/06/2025. The seller also disclosed three recent sales totaling 38,244 shares and $2,346,609 in gross proceeds across 09/02/2025, 10/01/2025, and 10/02/2025.

These items indicate insider liquidity rather than a single large block sale; compliance hinges on whether the trades follow a documented plan like Rule 10b5-1 and on the filer’s representation of no undisclosed material information. Monitor filing dates and any stated plan adoption date for clarity on pre-planned trading protection within the next weeks.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Ionis (IONS) report in this Form 144?

The filing reports a proposed sale of 6,849 shares of common stock $472,718) to be sold around 10/06/2025 via Stifel Nicolaus on Nasdaq.

How were the shares acquired that are being sold?

The shares were acquired as Restricted Stock Units on 01/15/2025 and the purchase was paid in cash on that date.

Who recently sold shares for the account referenced in the filing?

Eric Swayze sold 11,130, 14,142, and 12,972 shares on 09/02/2025, 10/01/2025, and 10/02/2025, respectively, totaling 38,244 shares and $2,346,609 in gross proceeds.

What fraction of Ionis shares does the proposed sale represent?

The proposed sale of 6,849 shares is a small fraction of the reported 159,391,229 shares outstanding.

Does the filing indicate a Rule 10b5-1 trading plan date?

No specific plan adoption date is provided in the notice; the filer references Rule 10b5-1 conditions but did not state a plan date.
Ionis Pharmaceuticals

NASDAQ:IONS

IONS Rankings

IONS Latest News

IONS Latest SEC Filings

IONS Stock Data

12.77B
160.75M
0.65%
108.48%
6.59%
Biotechnology
Pharmaceutical Preparations
Link
United States
CARLSBAD